Intuitive Surgical Inc

Intuitive Surgical Inc

ISRG

Get informed when a big investor buys or sells

+ Follow
Market Cap$122.33B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Intuitive Surgical IncIntuitive Surgical Inc41.3-17%10.7-

Earnings Call Q2 2026

July 16, 2026 - AI Summary

Q2 performance: strong growth led by da Vinci + ION adoption - Total procedures +16% YoY driven by da Vinci +15% and ION +36%. - Revenue +19% to $2.89B; recurring revenue +19% to $2.47B (85% of total). - Installed base growth: da Vinci systems +12% and ION systems +21%; exited quarter with ~13k systems installed worldwide. - Financial quality: non-GAAP operating margin 42%; non-GAAP EPS +28% YoY.
Regional / demand signals: US resilient but “deferrable cases” pressured; OUS mixed with China still a challenge - US da Vinci procedures +12%, with after-hours procedures +26%, but overall US growth moderated vs early-year expectations. - Management attributes pressure to patient behavior/coverage dynamics, specifically ACA premium subsidy expiration effects on patients with conditions that can be deferred (noted as a modest adverse impact; disease burden unchanged—expect eventual catch-up). - Outside US +20% da Vinci procedure growth ~in line, with Europe +20% and Asia +20%; rest of world +22%. - China remains challenging: lower tender activity, increased domestic robotic competition, and policy-driven pricing pressure; efforts ongoing via green channel processes and engagement on charge code policy.
Capital placements & platform momentum: da Vinci 5 and SP scaling; ION penetration broadening internationally - Q2 system placements: 468 da Vinci (+18% vs prior year) and 55 ION. - Da Vinci 5 strength: 246 da Vinci 5 placements, including 114 dual consoles; installed base of da Vinci 5 just over 1.7k systems used by >15k surgeons. - da Vinci SP placed 38 systems in Q2; SP procedures +61%. - US SP stapler adoption rising: used in ~60% of eligible cases (up from just under 40% last quarter). International broad launch across Europe + Korea, targeting Japan in Q3. - ION: procedures +36% to 48k, now >400k cumulatively; installed in 12 countries outside the US. Continued progress on ROSE/EBS programs.

Exclusive for Stockcircle Pro members

Sign upSign Up
$522.35

Target Price by Analysts

57.3% upsideIntuitive Surgical Target Price DetailsTarget Price
$130.52

Current Fair Value

60.7% downside

Overvalued by 60.7% based on the discounted cash flow analysis.

Share Statistics

Market cap$122.33 Billion
Enterprise Value$114.37 Billion
Dividend Yield$- (-)
Earnings per Share$8
Beta1.46
Outstanding Shares354,500,000

Return

Return on Equity17.15%ROE
Return on Assets15.04%
Return on Invested Capital18.01%

Valuation & Multiples

P/E Ratio41.27P/E Ratio
PEG170.14PEG
Price to Sales10.71Price to Sales
Price to Book Ratio6.51Price to Book Ratio
Enterprise Value to Revenue10.36
Enterprise Value to EBIT31.42
Enterprise Value to Net Income36
Total Debt to Enterprise0.01
Debt to Equity0.04Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
July 16, 2026
EPS Estimate
$2.48
Average shareholder expectation
Revenue Estimate
$2.83 B
Average shareholder expectation

Next Earnings Call

Expected Date
July 28, 2026
EPS Estimate
$2.48
Average shareholder expectation
Revenue Estimate
$2.82 B
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio9.0000 788.37%
Total Calls400 99.99%
Total Puts3,600 99.89%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %2.11% 80.34%
Total Invested$2.90B 97.86%
Investors Holding445 1947.00%

ESG Score

No data

About Intuitive Surgical Inc

CEO: Gary Guthart

Relevant Senate Committees

Joint Committee on Taxation

This committee directly influences the development and analysis of tax legislation, providing crucial revenue estimates. Its work directly impacts corporate tax structures and the overall tax burden on companies like Intuitive Surgical.

Finance

This powerful committee controls taxation, trade, and entitlement spending. Medicare and Medicaid reimbursement policies are critical for healthcare providers and, by extension, medical device manufacturers. Tax policy directly impacts ISRG's profitability.

Appropriations

This committee directly allocates federal spending. Its subcommittees determine funding for healthcare programs (e.g., NIH, VA) and scientific research, which directly impacts the market and R&D opportunities for medical device manufacturers like ISRG.

Health, Education, Labor, and Pensions

This committee regulates the FDA, which is the primary approval body for medical devices. Its oversight of NIH funding impacts medical research, and labor laws affect manufacturing costs, all directly critical to ISRG's business.

Judiciary

This committee's oversight of intellectual property laws is crucial for ISRG, which relies heavily on patents for its surgical robotics. Its antitrust jurisdiction can also influence M&A and market competition within the medical device industry.

Veterans' Affairs

As a manufacturer of surgical instruments, ISRG's products are likely used in VA hospitals. The committee's funding decisions directly impact government healthcare contractors and medical device procurement for veterans.